Financing led by The Venture City, Capital Factory, Scalpel Ventures and Evoce Capital; funds will be utilized to run multiple clinical studies in oncology to advance a novel and revolutionary red blood cell based liquid biopsy platform invented at the University of Pennsylvania.

本轮融资由The Venture City、Capital Factory、Scalpel Ventures和Evoce Capital领投；所筹资金将用于开展多项肿瘤学临床研究，以推进一项在宾夕法尼亚大学发明的新型革命性基于红细胞的液体活检平台。

PHILADELPHIA

费城

,

，

Sept. 1, 2026

2026年9月1日

/PRNewswire/ -- Senticell, Inc. ('Senticell' or the 'Company'), a biotechnology company pioneering a new class of liquid biopsy built on red blood cell (RBC)-bound nucleic acids, today announced the closing of an oversubscribed seed financing round approaching $7 million. The round drew participation from The Venture City, Capital Factory, Scalpel Ventures, Evoce Capital, as well as a group of high-net-worth individuals..

/美通社/ -- Senticell, Inc.（“Senticell”或“公司”）是一家开创基于红细胞（RBC）结合核酸的新型液体活检技术的生物技术公司，今日宣布完成一轮超额认购的近700万美元种子轮融资。本轮融资吸引了The Venture City、Capital Factory、Scalpel Ventures、Evoce Capital以及一群高净值个人投资者的参与。

'This financing reflects strong investor conviction in the underlying science and in our team's ability to translate that science into a scalable diagnostic platform,' said Neha Shah, Co-founder and Chief Executive Officer of Senticell. 'Being oversubscribed and welcoming a group of investors who understand the clinical need firsthand, gives us both the capital and the opportunity to rapidly advance what will be a major breakthrough in cancer diagnosis and ultimately treatment decision-making.'.

Senticell联合创始人兼首席执行官Neha Shah表示：“此次融资反映了投资者对底层科学以及我们团队将这一科学成果转化为可扩展诊断平台的能力的坚定信心。本次融资获得超额认购，并迎来一群 firsthand 了解临床需求的投资者，这不仅为我们提供了资金，更赋予我们加速推进这项将在癌症诊断及最终治疗决策方面实现重大突破的技术的机会。”

Senticell's liquid biopsy platform is exclusively licensed to the company from the University of Pennsylvania and is built on more than a decade of published, peer-reviewed research demonstrating red blood cells actively bind and retain disease-associated DNA and RNA. These unique insights were first identified by Dr.

Senticell的液体活检平台由宾夕法尼亚大学独家授权给该公司，其建立在十余年已发表且经同行评审的研究基础之上，这些研究证实红细胞能够主动结合并保留与疾病相关的DNA和RNA。这些独特见解最初由博士发现。

Nilam Mangalmurti, who is the scientific co-founder of Senticell and acts as the company's Chief Scientific Advisor..

尼拉姆·曼加尔穆尔蒂是Senticell的科学联合创始人，并担任公司首席科学顾问。

Since red blood cells are the body's most abundant cell type (an estimated 30 trillion in circulation), remain in circulation for roughly 120 days, and come into contact with every tissue in the body, they represent a largely untapped molecular diagnostic reservoir that can significantly lower limits of detection of liquid biopsy.

由于红细胞是人体内最丰富的细胞类型（估计循环系统中的红细胞数量约为30万亿个），在循环系统中停留约120天，并与身体中的每一个组织接触，因此它们代表了一个尚未被充分利用的分子诊断资源库，可以显著降低液体活检的检测限。

Senticell is rapidly advancing a proprietary RBC liquid biopsy platform to identify clinically actionable disease signals in oncology that today's plasma-based tests miss and enable more consistent application in early-stage disease and low-shedding tumor states..

Senticell 正在快速推进其专有的红细胞液体活检平台，以识别当前基于血浆的检测所遗漏的、具有临床可操作性的肿瘤疾病信号，并实现其在早期疾病和低脱落肿瘤状态下的更一致应用。

'Decades of research suggested that red blood cells were doing far more than carrying oxygen. Our discovery that red blood cells bind nucleic acids revealed that they could provide a distinct window into disease—one that may capture information not readily accessible through conventional liquid biopsies.

数十年的研究表明，红细胞的作用远不止输送氧气。我们发现红细胞能够结合核酸，这揭示出它们可为疾病研究提供一个独特的窗口——一种可能捕获通过传统液体活检难以获取的信息的窗口。

Importantly, we recognized that this biology could be harnessed for diagnostics. That insight led to the development of a new technology to isolate and rapidly analyze RBC-associated nucleic acids, including oncogenic driver mutations. We are now building on this discovery to develop a reliable diagnostic platform with the potential to transform cancer detection and improve patient lives,' said Dr.

“重要的是，我们认识到可以利用这一生物学特性进行诊断。这一洞察促使我们开发出一项新技术，用于分离并快速分析与红细胞相关的核酸，包括致癌驱动突变。我们现在正基于这一发现，开发一个可靠的诊断平台，该平台有望变革癌症检测并改善患者生活。”博士说。

Mangalmurti..

曼加尔穆尔蒂..

Central to Senticell's data package are two prospective clinical studies currently underway at Penn Medicine, together enrolling approximately 300 patients and comparing Senticell's red-cell signal against plasma-based tests and determining tissue concordance. The company is actively enrolling 200 lung and pancreatic cancer patients at UPenn, evaluating pre-surgical driver detection and recurrence monitoring, with completion in Q1 2027.

Senticell数据方案的核心是两项正在宾夕法尼亚大学医学院（Penn Medicine）进行的前瞻性临床研究，共招募约300名患者，旨在将Senticell的红细胞信号与基于血浆的检测方法进行比较，并评估组织一致性。该公司正在宾夕法尼亚大学积极招募200名肺癌和胰腺癌患者，以评估术前驱动基因检测及复发监测，研究预计将于2027年第一季度完成。

In addition, Senticell is providing RBC-based in-vitro analytical support for a clinical study (head & neck and cervical cancer cohorts, ~100 patients across UPenn and UPenn-Botswana) evaluating MRD and post-treatment monitoring, with results expected in Q4 2026. Finally, foundational work under Senticell's Sponsored Research Agreement with Penn Medicine is establishing rapid, culture-independent pathogen detection for sepsis and pneumonia on the RBC platform; the Company expects to formalize this into a dedicated clinical study following the completion of its oncology proof-of-concept work..

此外，Senticell 正在为一项评估微小残留病灶（MRD）及治疗后监测的临床研究提供基于红细胞的体外分析支持，该研究涵盖头颈癌和宫颈癌队列，涉及宾夕法尼亚大学及宾夕法尼亚大学-博茨瓦纳项目约100名患者，预计结果将于2026年第四季度公布。最后，根据 Senticell 与宾夕法尼亚大学医学院签订的赞助研究协议所开展的基础工作，正在建立基于红细胞平台的快速、非培养依赖性病原体检测方法，用于败血症和肺炎的诊断；公司预期在完成其肿瘤学概念验证工作后，将此项工作正式转化为一项专门的临床研究。

With its transformative technology based on decades of research, Senticell has attracted a world-class scientific advisory board including:

凭借基于数十年研究的变革性技术，Senticell 吸引了一支世界级的科学顾问委员会，其中包括：

Steven Albelda, MD

史蒂文·阿尔贝尔达，医学博士

(Penn Medicine, Emeritus), a tumor immunologist and co-founder of Capstan Therapeutics (acquired by AbbVie)

（宾夕法尼亚大学医学院，荣休教授），肿瘤免疫学家，Capstan Therapeutics 联合创始人（该公司已被艾伯维收购）

Chris Hunter, PhD

克里斯·亨特，博士

(Penn Vet), a cytokine biologist and founder of Surface Oncology (acquired by Coherus)

（宾夕法尼亚大学兽医学院），一位细胞因子生物学家，也是Surface Oncology（已被Coherus收购）的创始人

David Roth, MD, PhD

大卫·罗斯，医学博士，哲学博士

(Penn Medicine, Emeritus), founder of the Center for Personalized Diagnostics at UPenn.

（宾夕法尼亚大学医学院荣休教授），宾夕法尼亚大学个性化诊断中心创始人。

'I have closely followed Dr. Mangalmurti's research at Penn. Senticell will translate these basic science findings into clinically applicable RBC-platforms that will be more sensitive, more rapid, and less expensive than currently available testing approaches in diseases like cancer and infections,' said Dr.

“我密切关注了曼加尔穆尔蒂博士在宾夕法尼亚大学的研究。Senticell 公司将把这些基础科学发现转化为临床适用的红细胞平台，其在癌症和感染等疾病中的检测将比现有方法更灵敏、更快速且成本更低。”博士表示。

Steven Albelda, Scientific Advisor to Senticell..

史蒂文·阿尔贝尔达，Senticell 的科学顾问。

Looking ahead, Senticell views this seed round as the foundation for a much broader platform. 'Red blood cells have been hiding in plain sight as a diagnostic tool for decades, and we are just beginning to unlock what they can tell us,' said Shah. 'Our vision is to build the definitive RBC-based diagnostics platform, one that starts in oncology but ultimately extends across disease areas where earlier, more sensitive detection can change how patients are treated.

展望未来，Senticell 将本轮种子融资视为构建更广阔平台的基础。Shah 表示：“数十年来，红细胞作为一种诊断工具一直未被充分重视，而我们才刚刚开始解锁它们所能提供的信息。”我们的愿景是打造基于红细胞的权威诊断平台，该平台将从肿瘤学领域起步，并最终扩展至其他疾病领域，在这些领域中，更早、更灵敏的检测能够改变患者的治疗方式。

This is the first step toward making that a reality.'.

这是实现这一目标的第一步。

About Senticell

关于 Senticell

Senticell is a biotechnology company developing a new class of liquid biopsy diagnostics based on red blood cell (RBC)-bound nucleic acids. Founded on research pioneered at Penn Medicine, Senticell's platform is designed to unlock disease signals that plasma-based liquid biopsy often cannot detect, with initial applications in oncology and infectious diseases.

Senticell 是一家生物技术公司，正在开发基于红细胞（RBC）结合核酸的新型液体活检诊断技术。Senticell 的平台依托于宾夕法尼亚大学佩雷尔曼医学院开创的研究成果，旨在解锁基于血浆的液体活检往往无法检测到的疾病信号，其初始应用领域为肿瘤学和传染病。

Senticell holds an exclusive, worldwide license to its foundational RBC platform from the University of Pennsylvania and is based in Philadelphia, Pennsylvania. For more information, visit .

Senticell 拥有来自宾夕法尼亚大学的基础性红细胞（RBC）平台的全球独家许可，公司总部位于宾夕法尼亚州费城。欲了解更多信息，请访问。

www.senticell.bio

www.senticell.bio

.

。

SOURCE Senticell

来源 Senticell

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示